ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AEZS Stock Price » AEZS Stock News

Aeterna Zentaris Share News

 Aeterna Zentaris (mm) Stock Price
AEZS Stock Price
 Aeterna Zentaris (mm) Stock Chart
AEZS Stock Chart
 Aeterna Zentaris (mm) Stock News
AEZS Stock News
 Aeterna Zentaris (mm) Company Information
AEZS Company Information
 Aeterna Zentaris (mm) Stock Trades
AEZS Stock Trades

FDA Fast Tracks Keryx Colorectal Cancer Drug, Shares Soar

DOW JONES NEWSWIRES Keryx Biopharmaceuticals Inc. (KERX) said the U.S. Food and Drug Administration has given fast-track designation to perifosine, its drug for treating colorectal cancer. Shares of the biopharmaceutical company jumped 25% to $3.43 in recent trading, while U.S.-traded shares of Keryx's Canadian partner Aeterna Zentaris Inc. (AEZ.T, AEZS) were recently up 23% to 99 cents. Drugs given fast-track designation are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs, Keryx said. They usually qualify for expedited review from the FDA. "We believe that commercialization of perifosine in this indication could potentially commence by mid-2012," said Chief Executive Ron Bentsur. Keryx said it expects to begin Phase III testing of the drug in the second quarter of this year, and it expects to complete the study in the second half of 2011. Keryx in December received fast-track status from the FDA for perifosine for the treatment of multiple myeloma. The treatment is licensed by Keryx from Aeterna for the U.S., Canada and Mexico. -By Nathan Becker, Dow Jones Newswires; 212-416-2855;;

Stock News for Aeterna Zentaris (AEZS)
02/12/201608:07:35Amended Statement of Ownership (sc 13g/a)
02/01/201617:33:00Aeterna Zentaris to Participate in 18th Annual BIO CEO & Investor...
01/29/201608:30:00Aeterna Zentaris Announces Appointments to Board of Directors
01/26/201608:30:00Aeterna Zentaris Files International Patent Application for Novel...
01/25/201608:30:00Aeterna Zentaris Announces Additional Market Purchases of Common...
01/19/201608:30:00Aeterna Zentaris Concludes Successful Meeting of Clinical Investigators...
01/14/201615:24:03Amended Statement of Ownership (sc 13g/a)
01/13/201615:00:00Aeterna Zentaris Affirms Focus on Targeted Oncology During 2016...
01/12/201617:08:33Amended Registration Statement for Securities of Certain Canadian...
12/30/201516:06:00Aeterna Zentaris Announces Filing of Preliminary Base Shelf Prospectus
12/30/201512:07:36Appointment of Agent for Service of Process and Undertaking (f-x)
12/30/201511:36:19Registration Statement for Securities of Certain Canadian Issuers...
12/15/201514:09:24Report of Foreign Issuer (6-k)
12/14/201514:17:49Report of Foreign Issuer (6-k)
12/14/201512:30:00Aeterna Zentaris Announces Closing of US$16.65 Million Public...
12/09/201517:26:15Voluntary Supplemental Material Filed Pursuant to Section 11(a...
12/09/201512:39:55Report of Foreign Issuer (6-k)
12/09/201508:25:00Aeterna Zentaris Announces Pricing of US$16.65 Million Public...
12/09/201506:08:30Report of Foreign Issuer (6-k)
12/09/201506:05:49Voluntary Supplemental Material Filed Pursuant to Section 11(a...

Aeterna Zentaris and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations